Literature DB >> 17964017

Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome.

Rolf T Urbanus1, Ronald H M W Derksen, Philip G de Groot.   

Abstract

The diagnosis of the antiphospholipid syndrome, a non-inflammatory autoimmune disease characterized by thrombosis or pregnancy morbidity in the presence of antiphospholipid antibodies, depends greatly upon laboratory diagnostics. The diagnostic value of all available assays to detect antiphospholipid antibodies and the anticardiolipin assay in particular, is a matter of ongoing debate. Although the presence of lupus anticoagulant correlates best with thrombosis, accurate determination is not always possible due to anticoagulant treatment. Data on the predictive value of alternatives such as the anti-beta2-glycoprotein I and the anti-prothrombin antibody assay are insufficient and prospective cohort studies are needed. Determining antiphospholipid antibody profiles seems to increase diagnostic specificity. Substantial progress has been made in unravelling the pathophysiological mechanisms underlying the antiphospholipid syndrome. Several cellular receptors for antibody-beta2-glycoprotein I complexes have been identified and their roles in cellular activation are being investigated. In vivo data should provide more insight into the importance of the interaction with individual receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964017     DOI: 10.1016/j.blre.2007.09.001

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  12 in total

Review 1.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

2.  Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I.

Authors:  Nicola Pozzi; Alessandra Banzato; Samuele Bettin; Elisa Bison; Vittorio Pengo; Vincenzo De Filippis
Journal:  Protein Sci       Date:  2010-05       Impact factor: 6.725

Review 3.  The clinical significance of posttranslational modification of autoantigens.

Authors:  Maria G Zavala-Cerna; Erika A Martínez-García; Olivia Torres-Bugarín; Benjamín Rubio-Jurado; Carlos Riebeling; Arnulfo Nava
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

4.  Role of tumor necrosis factor-α in the extraintestinal thrombosis associated with colonic inflammation.

Authors:  Hideo Yoshida; Cigdem Erkuran Yilmaz; D Neil Granger
Journal:  Inflamm Bowel Dis       Date:  2010-12-16       Impact factor: 5.325

Review 5.  The clinical significance of coagulation and the inflammatory response in autoimmunity.

Authors:  Benjamín Rubio-Jurado; Paulina Iñiguez-Franco; Pedro A Reyes; Gustavo Robles; Mario Salazar-Páramo; Guadalupe Zavala-Cerna; Carlos Riebeling; Arnulfo Nava
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 6.  Antiphospholipid syndrome: A diagnostic challenge.

Authors:  R S Mallhi; Neerja Kushwaha; T Chatterjee; J Philip
Journal:  Med J Armed Forces India       Date:  2016-06-24

Review 7.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

8.  Structural insights into recognition of beta2-glycoprotein I by the lipoprotein receptors.

Authors:  Dmitri Beglov; Chang-Jin Lee; Alfredo De Biasio; Dima Kozakov; Ryan Brenke; Sandor Vajda; Natalia Beglova
Journal:  Proteins       Date:  2009-12

9.  A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome.

Authors:  Alexey Kolyada; Chang-Jin Lee; Alfredo De Biasio; Natalia Beglova
Journal:  PLoS One       Date:  2010-12-15       Impact factor: 3.240

Review 10.  Antiphospholipid syndrome.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Arthritis Res Ther       Date:  2008-12-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.